- Home
- HYPR vs IMMX Comparison
HYPR vs IMMX Comparison
Compare HYPR & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- IMMX
- Stock Information
- Founded
- HYPR 2014
- IMMX 2014
- Country
- HYPR United States
- IMMX United States
- Employees
- HYPR N/A
- IMMX N/A
- Industry
- HYPR Medical Specialities
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- HYPR Health Care
- IMMX Health Care
- Exchange
- HYPR Nasdaq
- IMMX Nasdaq
- Market Cap
- HYPR 54.6M
- IMMX 50.1M
- IPO Year
- HYPR N/A
- IMMX 2021
- Fundamental
- Price
- HYPR $0.61
- IMMX $1.98
- Analyst Decision
- HYPR Strong Buy
- IMMX Strong Buy
- Analyst Count
- HYPR 3
- IMMX 1
- Target Price
- HYPR $1.13
- IMMX $7.00
- AVG Volume (30 Days)
- HYPR 269.5K
- IMMX 60.4K
- Earning Date
- HYPR 05-13-2025
- IMMX 05-27-2025
- Dividend Yield
- HYPR N/A
- IMMX N/A
- EPS Growth
- HYPR N/A
- IMMX N/A
- EPS
- HYPR N/A
- IMMX N/A
- Revenue
- HYPR $11,732,000.00
- IMMX N/A
- Revenue This Year
- HYPR $24.00
- IMMX N/A
- Revenue Next Year
- HYPR $28.70
- IMMX N/A
- P/E Ratio
- HYPR N/A
- IMMX N/A
- Revenue Growth
- HYPR 0.34
- IMMX N/A
- 52 Week Low
- HYPR $0.58
- IMMX $1.26
- 52 Week High
- HYPR $1.90
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- HYPR 35.57
- IMMX 54.47
- Support Level
- HYPR $0.66
- IMMX $2.04
- Resistance Level
- HYPR $0.80
- IMMX $2.15
- Average True Range (ATR)
- HYPR 0.06
- IMMX 0.17
- MACD
- HYPR -0.00
- IMMX -0.00
- Stochastic Oscillator
- HYPR 8.94
- IMMX 45.16
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.